PMID- 26516724
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20170110
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 13
IP  - 2
DP  - 2016
TI  - A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: 
      ELLIPTA(R) Dry Powder Inhaler (DPI) versus DISKUS(R) DPI.
PG  - 167-75
LID - 10.3109/15412555.2015.1057274 [doi]
AB  - Patients' preference is an important factor in selecting an inhaler treatment for 
      COPD. The DISKUS(R) dry powder inhaler (DPI), which has been available to deliver 
      several COPD medications for a decade, and the ELLIPTA(R) DPI, developed for the 
      delivery of newer once-daily medications for patients with COPD, were studied in 
      terms of patient preference and inhaler-specific attributes. We conducted a 
      randomized, open-label, crossover study in patients with COPD. Patients used 
      placebo ELLIPTA DPI once daily and placebo DISKUS DPI twice daily, for  approximately 1 week 
      each, while continuing their COPD medications. Endpoints were: inhaler preference 
      based on size of the numbers on the dose-counter (primary); the number of steps 
      needed and inhaler size (secondary); and based on comfort of the mouthpiece, ease 
      of opening, overall preference, and dosing regimen preference ('other'). Safety 
      assessments included adverse events (AEs). A total of 287 patients were 
      randomized. A significantly (p < 0.001) larger proportion of patients preferred 
      the ELLIPTA DPI over DISKUS DPI for each of the tested attributes and overall, 
      and preferred once-daily over twice-daily dosing. AEs were reported for 36 
      patients (13%); one (dry mouth) was considered to be related to the 
      placebo-containing DISKUS DPI. Three patients had five non-fatal serious AEs, 
      none were deemed inhaler-related. This study demonstrated that more patients with 
      COPD preferred five specific inhaler attributes of the ELLIPTA DPI over DISKUS 
      DPI and overall, and preferred once-daily versus twice-daily dosing. Safety 
      profiles were consistent with those expected for COPD.
FAU - Yun Kirby, Suyong
AU  - Yun Kirby S
AD  - a 1 GSK, Research Triangle Park , North Carolina , USA.
FAU - Zhu, Chang-Qing
AU  - Zhu CQ
AD  - b 2 GSK, Uxbridge , Middlesex , United Kingdom.
FAU - Kerwin, Edward M
AU  - Kerwin EM
AD  - c 3 Clinical Research Institute of Southern Oregon , Medford , Oregon , USA.
FAU - Stanford, Richard H
AU  - Stanford RH
AD  - a 1 GSK, Research Triangle Park , North Carolina , USA.
FAU - Georges, George
AU  - Georges G
AD  - a 1 GSK, Research Triangle Park , North Carolina , USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01868009
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151030
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Bronchodilator Agents)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bronchodilator Agents/*administration & dosage
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Dry Powder Inhalers
MH  - Equipment Design
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Compliance
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - dosing frequency
OT  - drug delivery
OT  - inhaler attributes
OT  - patient adherence
OT  - patient preference
OT  - treatment outcomes
EDAT- 2015/10/31 06:00
MHDA- 2017/01/10 06:00
CRDT- 2015/10/31 06:00
PHST- 2015/10/31 06:00 [entrez]
PHST- 2015/10/31 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
AID - 10.3109/15412555.2015.1057274 [doi]
PST - ppublish
SO  - COPD. 2016;13(2):167-75. doi: 10.3109/15412555.2015.1057274. Epub 2015 Oct 30.